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MβCDCardiac myocytes endogenously express α and β adrenergic receptors, prototypes of the G-protein coupled
receptor superfamily. Depending upon the dose of norepinephrine (agonist) exposure, hypertrophy and
apoptosis are initiated by differential induction of two discrete constituents of the transcription factor AP-1,
i.e., FosB and Fra-1. We explored differential adrenergic signaling as a paradigm for understanding how
cholesterol dictates cells to choose hypertrophy or apoptosis. For this, we used fosB and fra-1 promoter–
reporter constructs for monitoring adrenergic signaling. We show that cholesterol depletion enhances
norepinephrine-mediated signaling in cardiac myocytes. Importantly, this increased signaling is reduced to
original level upon cholesterol replenishment. We used speciﬁc ligands for α and β adrenergic receptors and
show that the enhanced signaling upon cholesterol depletion is a combined effect of both α and β adrenergic
receptors. These results constitute the ﬁrst report demonstrating the effect of cholesterol on adrenergic
signaling using a direct end-point gene expression.βCD, methyl-β-cyclodextrin;
: +91 40 2716 0311.
).
l rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
Cholesterol is an essential and representative lipid in higher
eukaryotic cellular membranes and is crucial in membrane organiza-
tion, dynamics, function, and sorting [1,2]. Cholesterol is often
found distributed nonrandomly in domains in biological membranes
[1,3]. Current understanding of the organization of biological
membranes involves the concept of lateral heterogeneities in the
membrane, collectively termed as membrane domains. Many of these
domains (sometimes termed as ‘lipid rafts’) are thought to be
important for the maintenance of membrane structure and function,
although characterizing the spatiotemporal resolution of these
domains has proven to be challenging [3–6]. The idea of such
specialized membrane domains assumes signiﬁcance in cell biology
since physiologically important functions such as membrane sorting
and trafﬁcking, signal transduction processes, and the entry of
pathogens [3,7–9] have been attributed to these domains. Impor-
tantly, cholesterol plays a vital role in the function and organization
of membrane proteins and receptors such as G-protein coupled
receptors (GPCRs) [10–12].
The GPCR superfamily is the largest and most diverse protein
family in mammals, involved in signal transduction across mem-branes [13,14]. GPCRs are prototypical members of the family of seven
transmembrane domain proteins and include N800 members which
together constitute ~5% of the human genome [15]. GPCRs regulate
physiological responses to a diverse array of stimuli, and mediate
multiple physiological processes. For this reason, GPCRs have
emerged as major targets for the development of novel drug
candidates in all clinical areas [16]. It is estimated that up to 50% of
clinically prescribed drugs act as either agonists or antagonists of
GPCRs [17]. Adrenergic receptors are important members of the
GPCR superfamily and are endogenously expressed in cardiac
myocytes. In adult heart, terminally differentiated myocytes are
susceptible to discrete pathological consequences like hypertrophy,
apoptosis and autophagy, each with immense clinical implications
[18,19]. It has been reported that agonists such as angiotensin II
and norepinephrine (NE) may cause hypertrophy and apoptosis,
depending upon the concentration, thereby providing a frame-
work for understanding the crosstalk between these two pathways
[20–22]. NE released from the sympathetic nervous system and its
cognate receptors (α and β with several subtypes) play a critical
role in cardiac performance and homeostasis [23,24]. In addition,
ex vivo cardiac myocytes elicit hypertrophic response upon treatment
with lower dose (≤10 μM), while higher dose (≥50 μM) of NE
induces apoptosis [20,21]. However, in spite of signiﬁcant enhance-
ment of our knowledge of adrenergic signaling, the role of membrane
components such as cholesterol in these processes is not under-
stood yet. Such knowledge is crucial in a better understanding of
cardiovascular pathobiology, particularly keeping in mind the close
relationship between cholesterol, adrenergic signaling and heart
failure [25].
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for the function of GPCRs such as the serotonin1A receptor [11,12,26]
and the oxytocin receptor [27]. In this paper, we have explored
differential adrenergic signaling in cardiac myocytes as a paradigm for
understanding how cellular cholesterol dictates cells to choose
hypertrophic or apoptotic responses. We earlier demonstrated that
both ex vivo and in vivo myoblasts and myocytes elicit hypertrophic
and apoptotic responses through respective pathways, demarcated by
the induction of FosB and Fra-1, two distinct members of the AP-1
family of transcription factors [21]. These results have unequivocally
established a gene-speciﬁc framework for delineating differential
signaling leading to hypertrophic and apoptotic responses. In the
present study, we used fosB and fra-1 genes as the end-point targets
for analyzing respective signaling pathways, and monitored the effect
of cellular cholesterol on these pathways. Our results show that
cholesterol depletion enhances NE-mediated adrenergic signaling in
cardiac myocytes. Importantly, we used speciﬁc ligands for α and β
adrenergic receptors and our results show that signaling, as
monitored by activities of fosB and fra-1 promoters, is enhanced in
both types of receptors upon cholesterol depletion.
2. Materials and methods
2.1. Materials
All reagents used in this study were from Sigma Aldrich (St. Louis,
MO) unless mentioned otherwise. Fetal bovine serum was purchased
from Life Technologies (Carlsbad, CA). Luciferase assay reagents were
purchased from Promega (Madison, WI). Amplex Red cholesterol
assay kit was from Molecular Probes (Eugene, OR). Bradford reagent
was purchased from Bio-Rad (Hercules, CA). Water was puriﬁed




H9c2 cells (embryonic rat cardiac myoblasts) were cultured and
maintained as monolayer in Dulbecco's Modiﬁed Eagle's Medium
(DMEM) containing high glucose, supplemented with 10% fetal
bovine serum (heat inactivated), 90 U/ml penicillin, 90 μg/ml strep-
tomycin and 5 μg/ml amphotericin B at 37 °C in humidiﬁed incubator
with 5% CO2 [21].
2.2.2. Generation of promoter–reporter constructs
Fragments (1493 base pair and 2689 base pair) of 5′ upstream
regions of fosB and fra-1 genes were isolated by PCR ampliﬁcation
from rat genomic DNA and cloned in pGL3 luciferase basic vector
(Promega) using standard recombinant DNA methods [21]. Genomic
DNA isolated from H9c2 cells was PCR ampliﬁed using primers
(forward 5′ GGAATGGCAGGCTTTCAACAC 3′ and reverse 5′ CTGTGAC-
CACGCTGAGGTCTT 3′) spanning−1033 base pair to +460 base pair
of the 5′ upstream region of fosB gene. This 1493 bp PCR ampliﬁed
product was further cloned in pGL3 luciferase basic vector (Promega)
at SmaI site. Similarly, 2689 base pair PCR ampliﬁed product using fra1
speciﬁc primers (forward 5′ GTGCTAGCCCATGCGTGCTTGTGCGTGT 3′
and reverse 5′ CGAGATCTGCTGGATGT TCGGTA 3′) spanning −2474
base pair to+215 base pair regionwas cloned in pGL3 vector at Nhe I/
Bgl II sites.
2.2.3. Transient transfection
H9c2 cardiac myoblasts were grown in 6-well plate up to 60–70%
conﬂuency and transiently transfected with reporter plasmids using
Escort IV transfection reagent. Brieﬂy, 2 μg of plasmid DNA and 4 μl
of transfection reagent (Sigma) were used per well. Cells were
incubated with the transfection reagent in serum- and antibiotic-freemedium for 10–12 h, followed by incubation in medium containing
20% serum and antibiotics for 6 h. Cells were then kept in 10% serum
containing medium for 6 h. Finally, cells were kept in serum-free
medium for 12 h, treated with the agonists for 2 and 6 h (~36–40 h
post-transfection). The agonists used were NE, phenylephrine (α-
adrenergic receptor agonist) and isoproterenol (β-adrenergic recep-
tor agonist). Cells were harvested after 2 and 6 h of treatment for
reporter assay.
2.2.4. Luciferase reporter assays
Cells were lysed in reporter lysis buffer. Cell lysates were analyzed
for luciferase activity using the Luciferase Reagent Assay Kit and the
corresponding luminescence was measured with a luminometer
(Turner Scientiﬁc, CA). Normalization of transfection efﬁciency was
done by the estimation of total protein used for the luciferase assay [28].
2.2.5. Cholesterol depletion of cells in culture
Cells were grown in 6-well plate and transfected with reporter
constructs. Cholesterol depletion was carried out by treating cells
with 5 mMMβCD in serum-free medium for 30 min at 37 °C, followed
by wash with serum-free medium [29,30].
2.2.6. Replenishment of cholesterol in cholesterol-depleted cells
Cholesterol-depleted H9c2 cells were replenished with cholesterol
using a water-soluble cholesterol–MβCD complex. Cholesterol re-
plenishment was carried out by incubating cholesterol-depleted cells
with the cholesterol–MβCD complex for 5 min in a humidiﬁed
atmosphere with 5% CO2 at 37 °C [31]. The complex was prepared
by dissolving required amounts of cholesterol and MβCD in a ratio of
1:10 (mol/mol) in DMEM medium by constant vortexing at room
temperature (~23 °C) [26]. Cholesterol–MβCD complex was freshly
prepared and ﬁlter sterilized before each experiment.
2.2.7. Analysis of cholesterol content
Cholesterol content in cell lysates was estimated using the Amplex
Red cholesterol assay kit [32].
3. Results
The water-soluble compound MβCD has earlier been shown to
selectively and efﬁciently extract cholesterol from cellular mem-
branes by including it in a central nonpolar cavity [33]. Fig. 1 shows
the cholesterol content in cholesterol-depleted and cholesterol-
replenished H9c2 cardiac myocytes. Upon treatment of cells with
5 mM MβCD, the cholesterol content was reduced to ~48% of that of
control (without MβCD or agonist treatment) in case of cells
transfected with fosB plasmid (Fig. 1a). In case of cardiac myocytes
that were transfected with fra-1, the corresponding reduction in
cholesterol content was comparable (~50%; see Fig. 1b). Cholesterol
replenishment of cholesterol-depleted cells was carried out by
incubating the cholesterol-depleted cells with cholesterol–MβCD
complex, as described in Materials and methods. As shown in Fig.1,
replenishment of cholesterol with this complex resulted in recovery
of cholesterol. Similar results were obtained when cells were
stimulated by 2 μM (Fig. 1a) and 100 μM (Fig. 1b) NE.
Low and high doses (2 and 100 μΜ) of NE selectively induce the
transcription of fosB and fra-1 genes (Jindal and Goswami, manuscript
in preparation). This is based on the earlier observation that
hypertrophic and apoptotic doses of NE (2 and 100 μΜ, respectively)
differentially induce FosB and Fra-1 [21]. As shown in Fig. 2, fosB
promoter was induced (~1.5 fold) by 2 μM NE in 2 h and fra-1
promoter was induced (~2.5 fold) by 100 μM NE in 6 h in control
(without MβCD or agonist treatment) cells. It should be noted that
promoter activity appears to be modulated with cholesterol content,
even in the absence of agonist treatment. Interestingly, cholesterol
depletion enhances the induction of fosB promoter to ~2.4 fold upon
Fig. 1. Cholesterol content of H9c2 cells upon cholesterol depletion and replenishment.
H9c2 cells were transfected with (a) fosB and (b) fra-1 promoter–reporter constructs.
Cholesterol contents in control (without MβCD or agonist treatment; dotted bar),
cholesterol-depleted (crisscrossed bar), and cholesterol-replenished (hatched bar)
cells are shown. Corresponding cholesterol contents upon stimulation by 2 μM (panel
a) and 100 μM (panel b) NE are also shown. Values are expressed as percentages of
cholesterol content of control (without MβCD or agonist treatment) cells. Data
represent means±S.E. of at least four independent measurements. See Materials and
methods for other details.
Fig. 2. Effect of cholesterol depletion and replenishment of H9c2 cells on fosB and fra-1
promoter activity. H9c2 cells were transfected with (a) fosB and (b) fra-1 promoter–
reporter constructs. Control (without MβCD or agonist treatment; dotted bar),
cholesterol-depleted (crisscrossed bar), and cholesterol-replenished (hatched bar)
cells were stimulated with 2 and 100 μM NE for fosB (2 h) and fra-1 (6 h) promoter,
respectively. Cell lysates were assayed for luciferase activity. Fold induction represents
luciferase activities of respective constructs, normalized to control (without MβCD or
agonist treatment) cells. Data represent means±S.E. of at least four independent
measurements. See Materials and methods for other details.
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induction comes down to original level (~1.5 fold) upon cholesterol
replenishment. Similarly, cholesterol depletion enhances the induc-
tion of fra-1 promoter to ~4.9 fold by 100 μM NE and the enhanced
induction is reduced to more or less original level (~2.5 fold) upon
replenishment with cholesterol (Fig. 2b).
As mentioned earlier, H9c2 cardiac myocytes possess multiple
adrenergic receptors (α and β with several subtypes). In order to
explore whether the enhanced induction in fosB and fra-1 promoters
upon cholesterol depletion is due to speciﬁc receptor subtypes (α/β)
or due to a combination of these subtypes, we monitored the
induction of these promoters upon stimulation with subtype-speciﬁc
ligands.We used phenylephrine and isoproterenol as speciﬁc agonists
for α and β adrenergic receptors, respectively. Fig. 3a shows that
cholesterol depletion enhances the induction of fosB promoter to ~1.5
fold upon stimulation with 10 μM isoproterenol or phenylephrine.
Similarly, cholesterol depletion enhances the induction of fra-1
promoter by ~2.6 and 3.7 folds upon treatment with 100 μM
isoproterenol or 10 μM phenylephrine, respectively (Fig. 3b). Overall,
our results demonstrate that adrenergic signaling is enhanced upon
cholesterol depletion in cardiac myocytes, irrespective of subtype
speciﬁcity. These results are similar to our previous results in which
we demonstrated that cholesterol depletion from cells using MβCD
resulted in enhanced function of the serotonin1A receptor [29,30].
Taken together, our results represent the ﬁrst report describing the
effect of cholesterol on the function of adrenergic receptors, using a
direct end-point gene expression assay.4. Discussion
GPCRs are the most ubiquitous among mammalian cell surface
receptors and mediate numerous cellular events [34]. Adrenergic
receptors are important members of the GPCR superfamily and play
crucial role in cardiovascular biology and homeostasis
[21,23,24,35,36]. However, mechanisms by which adrenergic stimu-
lation results in activation/inactivation of cognate genes is still
emerging [35,36], particularly in the context of membrane lipids.
The molecular mechanism underlying the effect of membrane lipids
such as cholesterol on the structure and function of integral
membrane proteins and receptors is poorly understood and is an
active area of research [10,11,37,38]. It has been proposed that such
effects could occur either due to a speciﬁc molecular interaction with
membrane proteins leading to a conformational change in the
receptor [27], or due to alterations in the membrane physical
properties induced by the presence of cholesterol [39], or due to a
combination of both [37]. There is another mechanism by which
cholesterol could affect structure and function of membrane proteins.
This mechanism invokes the concept of ‘nonannular’ binding sites of
membrane lipids. Interestingly, we recently proposed that cholesterol
binding sites in GPCRs could represent nonannular binding sites [38].
Our earlier results showed that hypertrophic and apoptotic
responses elicited by NE are marked by the differential induction of
FosB and Fra-1 [21]. We conﬁrmed these observations using 2 and
100 μΜ doses of NE which selectively induce the transcription of fosB
and fra-1 genes, respectively (Jindal and Goswami, manuscript in
Fig. 3. Effect of cholesterol depletion of H9c2 cells on fosB and fra-1 promoter activity
upon stimulation with speciﬁc agonists of α- and β-adrenergic receptors. H9c2 cells
were transfected with (a) fosB and (b) fra-1 promoter–reporter constructs. Control
(without MβCD or agonist treatment; dotted bar) and cholesterol-depleted (criss-
crossed bar) cells were treated with 10 μM isoproterenol or phenylephrine for fosB, and
100 μM isoproterenol or 10 μM phenylephrine for fra-1 promoter. Cell lysates were
assayed for luciferase activity. Fold induction represents luciferase activities of
respective constructs, normalized to control (without MβCD or agonist treatment)
cells. Data represent means±S.E. of at least four independent measurements. See
Materials and methods for other details.
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enhances the induction of fosB and fra-1 promoters upon stimulation
with NE and this increased induction is restored upon cholesterol
replenishment. H9c2 cardiac myocytes endogenously express several
adrenergic receptors (α and βwith many subtypes). We used speciﬁc
ligands (phenylephrine and isoproterenol) againstα and β adrenergic
receptors to delineate the enhanced induction in fosB and fra-1
promoters. Our results demonstrate that the enhanced induction in
fosB and fra-1 promoters upon cholesterol depletion is a combined
effect of both α and β subtypes of adrenergic receptors. Taken
together, these novel results demonstrate the effect of cholesterol
depletion on the function of adrenergic receptors, using a direct end-
point gene expression assay. These results are in agreement with our
earlier results with a closely related GPCR, the serotonin1A receptor
[29,30]. Interestingly, the β2-adrenergic receptor and the serotonin1A
receptor enjoy ~43% amino acid similarity in the transmembrane
region. In fact, it is due to this close similarity, the intronless genomic
clone (G-21) encoding the serotonin1A receptor showed cross-
hybridization with a full length β-adrenergic receptor probe at
reduced stringency [40].
Interestingly, the function of α and β adrenergic receptors is
reported to bemodulated by cholesterol. It has been recently reported
that cholesterol depletion using MβCD increases the α1A-adrenergic
receptor-dependent signaling upon ligand stimulation [41]. In
addition, cholesterol depletion is reported to enhance β2-adrenergic
receptor-associated signaling, while increased cholesterol content
inhibited the signaling [42]. Cholesterol has also been shown toimprove the stability of the β2-adrenergic receptor [43], and appears
to be necessary for crystallization of the receptor [44]. The recent
crystal structure of the β2-adrenergic receptor has revealed structural
evidence of a speciﬁc cholesterol binding site [45]. Importantly, our
present results constitute one of the ﬁrst reports showing the effect of
cholesterol on the end-point signaling of the adrenergic receptor.
As mentioned earlier, ~50% of clinically prescribed drugs act as
either agonists or antagonists of GPCRs with several ligands of GPCRs
among the top 100 globally selling drugs, which points out their
immense therapeutic potential [17]. Interestingly, although GPCRs
represent major drug targets, only a small fraction of all GPCRs are
presently targeted by drugs [46]. This points out the exciting
possibility that the receptors which are not recognized yet could be
potential drug targets for diseases that are difﬁcult to treat by
currently available drugs. GPCRs such as adrenergic receptors are
involved in a number of physiological functions and represent
important drug targets [47]. Although the pharmacological and
signaling features of these receptors have been extensively studied,
aspects related to their interaction with membrane lipids have been
addressed in very few cases. Progress in deciphering molecular details
on the nature of the interaction of adrenergic receptors with
cholesterol would enhance our ability to design better therapeutic
strategies to combat diseases related to malfunctioning of these
receptors.
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